Form D · Pharmaceuticals
Vero Biotech Inc.
Atlanta, GA · CIK 0001359620
Offering snapshot reported Dec 22, 2021 · SEC filing
- Reported sold
- $27.3M Offering amount: $99.5M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 8, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 22, 2021 | Initial | $27,265,773 | No comparison | 5 | SEC filing |
| Sep 29, 2017 | Initial | $29,941,000 | No comparison | 31 | SEC filing |
| Oct 18, 2013 | Amendment | $14,738,606 | $168,000vs Oct 3, 2013 | 41 | SEC filing |
| Oct 3, 2013 | Initial | $14,570,606 | No comparison | 39 | SEC filing |
| Dec 29, 2011 | Initial | $7,990,819 | No comparison | 21 | SEC filing |
| Sep 14, 2009 | Initial | $2,136,030 | No comparison | 18 | SEC filing |
| Sep 14, 2009 | Initial | $2,136,030 | No comparison | 18 | SEC filing |
| Nov 27, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 6, 2006 | Paper | Not reported | No comparison | Not reported |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-426342
Source: Form D, filed Dec 22, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Paul Antinori | Executive |
| Eric Bednarski | Director |
| Todd Brady | Director |
| Roberto Cohen | Executive |
| Kurt Dasse | Director, Executive |
| David Fine | Director, Executive |
| David H. Fine, Ph.D. | Director, Executive |
| Brent V. Furse | Director, Executive |
| T. Scott Johnson, M.D. | Director |
| Anthony Loumidis | Executive |
| Theo Melas Kyriazi | Director |
| James O'brien | Director |
| Vinzenz Ploerer | Director |
| Robert Roscigno | Executive |
| Daniel Salazar | Director |
| Dan Salazar, Ph.D. | Director |
| Steven Shulman | Director |
| Tod Shultz | Executive |
| Thiago Tavares | Director |
| Shasha Zou | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
387 Technology Cir. Nw Suite 125
Atlanta, GA, 30313
Atlanta, GA, 30313